Literature DB >> 27665480

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival.

Pamela Samson1, Traves Crabtree1, Stephen Broderick2, Daniel Kreisel1, A Sasha Krupnick1, G Alexander Patterson1, Bryan Meyers1, Varun Puri3.   

Abstract

BACKGROUND: National organizations have recommended quality measures for operations in early-stage non-small cell lung cancer (NSCLC). The outcomes of adherence to these guidelines are unknown.
METHODS: Information about patients who underwent an operation for clinical stage I NSCLC was abstracted from the National Cancer Database. After reviewing current guidelines, the following quality measures were selected: anatomic resection, operation within 8 weeks of diagnosis, achievement of negative surgical margins, and sampling of 10 or more lymph nodes. Multivariate models identified variables independently associated with receiving quality measures and a Cox model created to evaluate overall survival.
RESULTS: Between 2004 and 2013, 133,026 of 133,366 (99.7%), 126,598 of 133,366 (94.9%), 91,472 of 133,366 (68.6%), and 30,041 of 133,366 (22.5%) patients met one, two, three, or four measures. Income of at least $38,000/year (odds ratio [OR] 1.20, 95% CI: 1.15 to 1.24), insurance type (private insurance: OR 1.22, 95% CI: 1.09 to 1.36; Medicare: OR 1.16, 95% CI:1.04 to 1.30), centers with at least 38 cases/year (OR 1.18, 95% CI: 1.14 to 1.22), academic institutions (OR 1.31, 95% CI: 1.27 to 1.35), and clinical stage IB patients (OR 1.50, 95% CI: 1.40 to 1.60) were more likely to meet all four measures; whereas increasing age (OR 0.99, 95% CI: 0.99 to 0.99), women (OR 0.93, 95% CI: 0.91 to 0.96), non-Caucasian race (OR 0.83, 95% CI: 0.79 to 0.87), and increasing Charlson/Deyo comorbidity score (1: OR 0.90, 95% CI: 0.87 to 0.93; ≥2: OR 0.82, 95% CI: 0.79 to 0.86) were associated with lower likelihood. Pathologic upstaging (hazard ratio [HR] 1.84, 95% CI: 1.78 to 1.89) and meeting all four measures (HR 0.39, 95% CI: 0.31 to 0.48) were most powerfully associated with overall survival.
CONCLUSIONS: National adherence to quality measures in stage I NSCLC resection is suboptimal. Guideline compliance is strongly associated with survival, and vigorous efforts should be instituted by national societies to improve adherence.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27665480      PMCID: PMC5182109          DOI: 10.1016/j.athoracsur.2016.07.003

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  21 in total

1.  Use of a surgical specimen-collection kit to improve mediastinal lymph-node examination of resectable lung cancer.

Authors:  Raymond U Osarogiagbon; Laura E Miller; Robert A Ramirez; Christopher G Wang; Thomas F O'Brien; Xinhua Yu; Alim Khandekar; Glenn P Schoettle; Samuel G Robbins; Edward T Robbins; Jeffrey B Gibson
Journal:  J Thorac Oncol       Date:  2012-08       Impact factor: 15.609

2.  Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database.

Authors:  Subroto Paul; Nasser K Altorki; Shubin Sheng; Paul C Lee; David H Harpole; Mark W Onaitis; Brendon M Stiles; Jeffrey L Port; Thomas A D'Amico
Journal:  J Thorac Cardiovasc Surg       Date:  2010-02       Impact factor: 5.209

3.  Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer.

Authors:  Pamela Samson; Aalok Patel; Tasha Garrett; Traves Crabtree; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2015-04-16       Impact factor: 4.330

4.  Impact of adjuvant treatment for microscopic residual disease after non-small cell lung cancer surgery.

Authors:  Jacquelyn G Hancock; Joshua E Rosen; Alberto Antonicelli; Amy Moreno; Anthony W Kim; Frank C Detterbeck; Daniel J Boffa
Journal:  Ann Thorac Surg       Date:  2014-12-17       Impact factor: 4.330

5.  Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer.

Authors:  Michelle S Ludwig; Michael Goodman; Daniel L Miller; Peter A S Johnstone
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

6.  Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer.

Authors:  Sai-Hong Ignatius Ou; Jason A Zell
Journal:  J Thorac Oncol       Date:  2008-08       Impact factor: 15.609

7.  Oncologic outcomes of segmentectomy compared with lobectomy for clinical stage IA lung adenocarcinoma: propensity score-matched analysis in a multicenter study.

Authors:  Yasuhiro Tsutani; Yoshihiro Miyata; Haruhiko Nakayama; Sakae Okumura; Shuji Adachi; Masahiro Yoshimura; Morihito Okada
Journal:  J Thorac Cardiovasc Surg       Date:  2013-03-08       Impact factor: 5.209

8.  Lymph node evaluation achieved by open lobectomy compared with thoracoscopic lobectomy for N0 lung cancer.

Authors:  Robert E Merritt; Chuong D Hoang; Joseph B Shrager
Journal:  Ann Thorac Surg       Date:  2013-07-31       Impact factor: 4.330

9.  Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non-small cell lung cancer.

Authors:  Raymond U Osarogiagbon; Obiageli Ogbata; Xinhua Yu
Journal:  Ann Thorac Surg       Date:  2013-11-20       Impact factor: 4.330

10.  Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  John A Howington; Matthew G Blum; Andrew C Chang; Alex A Balekian; Sudish C Murthy
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

View more
  21 in total

1.  Resection of the irradiated esophagus: the impact of lymph node yield on survival.

Authors:  V R Esposito; B A Yerokun; M S Mulvihill; M L Cox; B Y Andrew; C J Yang; A Y Choi; C Moore; T A D'Amico; B C Tong; M G Hartwig
Journal:  Dis Esophagus       Date:  2020-10-12       Impact factor: 3.429

2.  Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer.

Authors:  Meredith A Ray; Nicholas R Faris; Matthew P Smeltzer; Carrie Fehnel; Cheryl Houston-Harris; Paul Levy; Lynn Wiggins; Vishal Sachdev; Todd Robbins; David Spencer; Raymond U Osarogiagbon
Journal:  Ann Thorac Surg       Date:  2018-03-11       Impact factor: 4.330

Review 3.  Oncologic Quality Indicators in Thoracic Surgery.

Authors:  Jessica Hudson; Tara Semenkovich; Varun Puri
Journal:  Thorac Surg Clin       Date:  2017-08       Impact factor: 1.750

4.  Prognosis of upstaged N1 and N2 disease after curative resection in patients with clinical N0 non-small cell lung cancer.

Authors:  Jae Kil Park; Youngkyu Moon
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

5.  Review of Cancer-Specific Quality Measures Promoting the Avoidance of Low-Value Care.

Authors:  Brandon L Ellsworth; Allan K Metz; Nicole M Mott; Ruby Kazemi; Michael Stover; Tasha Hughes; Lesly A Dossett
Journal:  Ann Surg Oncol       Date:  2022-02-06       Impact factor: 5.344

6.  Comparison between Veteran and Non-Veteran Populations with Clinical Stage I Non-Small Cell Lung Cancer Undergoing Surgery.

Authors:  Brendan T Heiden; Daniel B Eaton; Su-Hsin Chang; Yan Yan; Martin W Schoen; Mayank R Patel; Daniel Kreisel; Ruben G Nava; Bryan F Meyers; Benjamin D Kozower; Varun Puri
Journal:  Ann Surg       Date:  2021-05-11       Impact factor: 12.969

7.  Consolidation/Tumor Ratio on Chest Computed Tomography as Predictor of Postoperative Nodal Upstaging in Clinical T1N0 Lung Cancer.

Authors:  Youngkyu Moon; Jae Kil Park; Kyo Young Lee; Min Namkoong; Seha Ahn
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

8.  Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.

Authors:  Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Raymond U Osarogiagbon
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

9.  Institutional factors associated with adherence to quality measures for stage I and II non-small cell lung cancer.

Authors:  Rhami Khorfan; David T Cooke; Robert A Meguid; Leah Backhus; Thomas K Varghese; Farhood Farjah; Karl Y Bilimoria; David D Odell
Journal:  J Thorac Cardiovasc Surg       Date:  2020-07-29       Impact factor: 6.439

10.  Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non-Small Cell Lung Cancer.

Authors:  Brendan T Heiden; Daniel B Eaton; Kathryn E Engelhardt; Su-Hsin Chang; Yan Yan; Mayank R Patel; Daniel Kreisel; Ruben G Nava; Bryan F Meyers; Benjamin D Kozower; Varun Puri
Journal:  JAMA Netw Open       Date:  2021-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.